MedTrace Logo

Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study

NCT03270995 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2020-02-20

No results posted yet for this study

Summary

Studies show that cancer survivors have unmet needs, the most frequently cited being fear of recurrence (FCR). Moderate to high levels of FCR have been reported by as much as 49% of cancer patients and are more prevalent among women. FCR is associated with psychological distress, lower quality of life, and increased health care utilization. Little evidence exists that these problems are being addressed by current medical management.

Conditions

  • Breast Neoplasms
  • Ovarian Neoplasms
  • Endometrial Neoplasms
  • Uterine Cervical Neoplasms

Interventions

BEHAVIORAL

Cognitive Existential Therapy Group 1

Six group sessions of two hour each using a cognitive-existential group approach

BEHAVIORAL

Supportive Therapy Group 2

Six group session of two hour each using a supportive group approach.

Sponsors & Collaborators

  • Canadian Cancer Society (CCS)

    collaborator OTHER

  • Princess Margaret Hospital, Canada

    collaborator OTHER

  • University of Ottawa

    collaborator OTHER

  • Sir Mortimer B. Davis - Jewish General Hospital

    collaborator OTHER

  • McGill University

    lead OTHER

Principal Investigators

  • Christine Maheu, RN, PhD · McGill University and University Health Network

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2020-02-01
Completion
2020-02-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03270995 on ClinicalTrials.gov